| Identification | Back Directory | [Name]
F 16915 | [CAS]
92510-91-3 | [Synonyms]
F 16915
4,7,10,13,16,19-Docosahexaenoic acid, 3-pyridinylmethyl ester, (4Z,7Z,10Z,13Z,16Z,19Z)- | [Molecular Formula]
C28H37NO2 | [MOL File]
92510-91-3.mol | [Molecular Weight]
419.6 |
| Chemical Properties | Back Directory | [Boiling point ]
528.9±38.0 °C(Predicted) | [density ]
0.982±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C, protect from light | [solubility ]
Soluble in DMSO | [form ]
Oil | [pka]
4.26±0.10(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
F 16915, is a docosahexaenoic acid derivative which can prevent heart failure-induced atrial fibrillation. | [in vivo]
F 16915 (100 mg/kg; daily oral gavage for 2 months) reduces marked dilation of the left atrial (LA) cavity and the steep decline of left ventricular (LV) contractile function occurring 2 months after infarction and reperfusion in rats[1].
F 16915 (1-5 g/day for 4 weeks) significantly reduces the infarct size and prevents the left ventricular free wall thinning[1]. | Animal Model: | Male Sprague-Dawley rats (220-300 g) with heart failure induced by occlusion of left descending coronary artery and 2 months reperfusion[1] | | Dosage: | 100 mg/kg | | Administration: | Daily oral gavage | | Result: | Reduced the infarct size.
Prevented the left ventricular free wall thinning.
Reduced the de-phosphorylation of connexin43 from atria tissue.
|
| [storage]
-20°C, protect from light |
|
|